{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:03:00Z","timestamp":1740106980996,"version":"3.37.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,10,10]],"date-time":"2016-10-10T00:00:00Z","timestamp":1476057600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s00520-016-3430-9","type":"journal-article","created":{"date-parts":[[2016,10,10]],"date-time":"2016-10-10T02:17:31Z","timestamp":1476065851000},"page":"4835-4837","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Managing neutropenia by pegfilgrastim in patients affected by relapsed\/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-5436","authenticated-orcid":false,"given":"Claudio","family":"Cerchione","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucio","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Peluso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Nappi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Di Perna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalila","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Migliaccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Picardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,10]]},"reference":[{"key":"3430_CR1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100:228\u2013237","journal-title":"Cancer"},{"key":"3430_CR2","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00520-008-0430-4","volume":"16","author":"R Pettengell","year":"2008","unstructured":"Pettengell R, Schwenkglenks M, Leonard R et al (2008) Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 16:1299\u20131309","journal-title":"Support Care Cancer"},{"unstructured":"United States Department of Health & Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Published: May 28, 2009 (v4.03: June 14, 2010)","key":"3430_CR3"},{"key":"3430_CR4","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187\u20133205","journal-title":"J Clin Oncol"},{"issue":"10","key":"3430_CR5","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.6004\/jnccn.2013.0148","volume":"11","author":"J Crawford","year":"2013","unstructured":"Crawford J, Armitage J, Balducci L, Becker PS, Blayney DW, Cataland SR, Heaney ML, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Steensma DP, Talbott M, Vadhan-Raj S, Westervelt P, Westmoreland M, Dwyer M, Ho M (2013) National comprehensive cancer network. Myeloid growth factors. J Natl Compr Cancer Netw 11(10):1266\u20131290","journal-title":"J Natl Compr Cancer Netw"},{"issue":"2","key":"3430_CR6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00520-014-2490-y","volume":"23","author":"C Cerchione","year":"2015","unstructured":"Cerchione C, Catalano L, Pareto AE, Picardi M, Pane F (2015) Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience. Support Care Cancer 23(2):301\u2013302","journal-title":"Support Care Cancer"},{"key":"3430_CR7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/annonc\/mdg019","volume":"14","author":"MD Green","year":"2003","unstructured":"Green MD, Koelbl H, Baselga J et al (2003) A randomized doubleblind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29\u201335","journal-title":"Ann Oncol"},{"key":"3430_CR8","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1634\/theoncologist.12-12-1416","volume":"12","author":"L Balducci","year":"2007","unstructured":"Balducci L et al (2007) Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 12:1416\u20131424","journal-title":"Oncologist"},{"issue":"7","key":"3430_CR9","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1182\/blood-2013-08-521468","volume":"123","author":"H Ludwig","year":"2014","unstructured":"Ludwig H, Kasparu H, Leitgeb C, Rauch et al (2014) Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood 123(7):985\u2013991","journal-title":"Blood"},{"doi-asserted-by":"crossref","unstructured":"Link H, Nietsch J, Kerkmann M, Ortner P (2015) Supportive Care Group (ASORS) of the German Cancer Society (DKG). Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy-a representative sample survey in Germany. Support Care Cancer.","key":"3430_CR10","DOI":"10.1007\/s00520-015-2779-5"},{"issue":"3","key":"3430_CR11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/hon.978","volume":"29","author":"F Ferrara","year":"2011","unstructured":"Ferrara F, Izzo T, Criscuolo C, Ricciardi C, Viola A, Delia R, Carbone A, Celentano M (2011) Comparison of fixed dose pegfilgrastim and daily filgrastim after autologous stem cell transplantation in patients with multiple myeloma autografted on a outpatient basis. Hematol Oncol 29(3):139\u2013143","journal-title":"Hematol Oncol"},{"issue":"1","key":"3430_CR12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1743-7563.2010.01355.x","volume":"7","author":"A Chan","year":"2011","unstructured":"Chan A, Leng XZ, Chiang JY, Tao M, Quek R, Tay K, Lim ST (2011) Comparison of daily filgrastim and pegfilgrastim to prevent febrile neutropenia in Asian lymphoma patients. Asia Pac J Clin Oncol 7(1):75\u201381","journal-title":"Asia Pac J Clin Oncol"},{"issue":"7","key":"3430_CR13","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1007\/s00520-014-2555-y","volume":"23","author":"G Kourlaba","year":"2015","unstructured":"Kourlaba G, Dimopoulos MA, Pectasides D, Skarlos DV, Gogas H, Pentheroudakis G, Koutras A, Fountzilas G, Maniadakis N (2015) Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer. Support Care Cancer 23(7):2045\u20132051","journal-title":"Support Care Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3430-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-016-3430-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3430-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T08:00:07Z","timestamp":1568448007000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-016-3430-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,10]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["3430"],"URL":"https:\/\/doi.org\/10.1007\/s00520-016-3430-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2016,10,10]]}}}